AiCuris: Dr. Alex Birkmann on Antiviral Drug Development for HSV

Alexander Birkmann, PhD, is a seasoned pharmaceutical professional with over 20 years of experience in antiviral drug development. He has held key positions at Bayer and AiCuris, contributing to the advancement of innovative anti-infective therapies. As Vice President of Virology and HSV Platform at AiCuris, he leads the scientific strategies for the NDA filing and line extension of pritelivir. His expertise spans from early-stage research to late-stage clinical trials, with a focus on herpes simplex virus (HSV) therapeutics.

Please register for the Zoom in advance here.